NERV Minerva Neurosciences Inc
- Stocks
- Healthcare
- NASDAQ: NERV
Price (delayed)
$3.635
Market cap
$25.42M
P/E Ratio
2.46
Dividend/share
N/A
EPS
$1.48
Enterprise value
$70.07M
Relative Growth:
Rel. Growth:
24
Relative Strength:
Rel. Strength:
94
Relative Valuation:
Rel. Valuation:
93
Relative Profitability:
Rel. Profitability:
32
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
Highlights
The company's net income has surged by 133% YoY and by 80% QoQ
The EPS has surged by 133% year-on-year and by 80% since the previous quarter
Minerva Neurosciences's equity has increased by 28% YoY but it has decreased by 10% QoQ
The company's quick ratio fell by 32% QoQ and by 18% YoY
Key stats
What are the main financial stats of NERV
Market
Valuations
Earnings
Shares outstanding
6.99M
Market cap
$25.42M
Enterprise value
$70.07M
Price to earnings (P/E)
2.46
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
PEG
0.02
EV/EBIT
6.24
EV/EBITDA
6.23
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.17M
Net income
$11.23M
EBIT
$11.23M
EBITDA
$11.24M
Free cash flow
-$15.63M
Per share
Balance sheet
Liquidity
EPS
$1.48
EPS diluted
$1.48
Free cash flow per share
-$2.07
Book value per share
-$4.59
Revenue per share
$0
TBVPS
$2.05
Total assets
$30.42M
Total liabilities
$62.53M
Debt
$60M
Equity
-$32.11M
Working capital
$13.02M
Debt to equity
-1.87
Current ratio
6.15
Quick ratio
6.07
Net debt/EBITDA
3.97
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
31.4%
Return on equity
N/A
Return on invested capital
19.4%
Return on capital employed
40.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NERV stock price
How has the Minerva Neurosciences stock price performed over time
Intraday
-4.84%
1 week
-10.02%
1 month
69.9%
1 year
57.36%
YTD
63.62%
QTD
72.68%
Financial performance
How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.17M
Net income
$11.23M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 133% YoY and by 80% QoQ
NERV's operating income is up by 38% year-on-year and by 15% since the previous quarter
Price vs fundamentals
How does NERV's price correlate with its fundamentals
Growth
What is Minerva Neurosciences's growth rate over time
Valuation
What is Minerva Neurosciences stock price valuation
P/E
2.46
P/B
N/A
P/S
N/A
EV/EBIT
6.24
EV/EBITDA
6.23
EV/Sales
N/A
The EPS has surged by 133% year-on-year and by 80% since the previous quarter
Minerva Neurosciences's equity has increased by 28% YoY but it has decreased by 10% QoQ
Efficiency
How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has surged by 151% YoY and by 100% QoQ
The return on invested capital has surged by 146% year-on-year and by 98% since the previous quarter
Dividends
What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NERV.
Financial health
How did Minerva Neurosciences financials performed over time
The total assets is 51% less than the total liabilities
The total assets has contracted by 34% YoY and by 7% from the previous quarter
Minerva Neurosciences's current ratio has decreased by 33% QoQ and by 18% YoY
The debt has contracted by 31% YoY
Minerva Neurosciences's equity has increased by 28% YoY but it has decreased by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.